Incorporating Clinicopathological and Molecular Risk Prediction Tools To Improve Outcomes in Early HR+/HER2– Breast Cancer

The authors examine the evidence for clinicopathological and molecular risk prediction tools in clinical practice and offer a perspective of potential future risk stratification strategies in the setting of hormone receptor–positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer.